Molecular Heterogeneity of Xp11.2 Translocation Renal Cell Carcinoma: The Correlation Between Split Signal Pattern in FISH and Prognosis

References

• Argani P, Antonescu C, Illei P, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159(1):179–192. doi:10.1016/S0002-9440(10)61684-711438465
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49(5):798–805. doi:10.1016/j.eururo.2005.11.03516442207
   PubMed Web of Science ®Google Scholar
• Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.02926935559
   PubMed Web of Science ®Google Scholar
• Geller JI, Ehrlich PF, Cost NG, et al. Characterization of adolescent and pediatric renal cell carcinoma: a report from the Children’s Oncology Group study AREN03B2. Cancer. 2015;121(14):2457–2464. doi:10.1002/cncr.2936825845370
   PubMed Web of Science ®Google Scholar
• Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009;15(4):1170–1176. doi:10.1158/1078-0432.CCR-08-118319228722
   PubMed Web of Science ®Google Scholar
• Sukov WR, Hodge JC, Lohse CM, et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol. 2012;36(5):663. doi:10.1097/PAS.0b013e31824dd97222498819
   PubMed Web of Science ®Google Scholar
• Argani P, Antonescu C, Couturier J, et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol. 2002;26(12):1553–1566. doi:10.1097/00000478-200212000-0000312459622
   PubMed Web of Science ®Google Scholar
• Clark J, Lu Y, Sidhar S, et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene. 1997;15(18):2233–2239. doi:10.1038/sj.onc.12013949393982
   PubMed Web of Science ®Google Scholar
• Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6):750–761. doi:10.1097/00000478-200306000-0000512766578
   PubMed Web of Science ®Google Scholar
• Xia Q-Y, Wang Z, Chen N, et al. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement. Mod Pathol. 2017;30(3):416–426. doi:10.1038/modpathol.2016.20427934879
   PubMed Web of Science ®Google Scholar
• Argani P, Zhang L, Reuter VE, et al. RBM10-TFE3 renal cell carcinoma: a potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH. Am J Surg Pathol. 2017;41(5):655.28296677
   PubMed Web of Science ®Google Scholar
• Malouf GG, Su X, Yao H, et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res. 2014;20(15):4129–4140. doi:10.1158/1078-0432.CCR-13-303624899691
   PubMed Web of Science ®Google Scholar
• Huang W, Goldfischer M, Babayeva S, et al. Identification of a novelPARP14-TFE3gene fusion from 10-year-old FFPE tissue by RNA-seq. Genes Chromosomes Cancer. 2015;54(8):500–505. doi:10.1002/gcc.2226126032162
   PubMed Web of Science ®Google Scholar
• Argani P, Zhong M, Reuter VE, et al. TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers. Am J Surg Pathol. 2016;40(6):723–737. doi:10.1097/PAS.000000000000063126975036
   PubMed Web of Science ®Google Scholar
• Antic T, Taxy J, Alikhan M, Segal J. Melanotic translocation renal cell carcinoma with a novel ARID1B-TFE3 gene fusion. Am J Surg Pathol. 2017;41(11):1576–1580. doi:10.1097/PAS.000000000000092728877054
   PubMed Web of Science ®Google Scholar
• Classe M, Malouf GG, Su X, et al. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. Histopathology. 2017;70(7):1089–1097. doi:10.1111/his.1316728106924
   PubMed Web of Science ®Google Scholar
• Wang XT, Xia QY, Ye SB, et al. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations. Mod Pathol. 2018;31(9):1346–1360. doi:10.1038/s41379-018-0051-529713041
   PubMed Web of Science ®Google Scholar
• Pei J, Cooper H, Flieder DB, et al. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma. Mod Pathol. 2019;32(5):710–716. doi:10.1038/s41379-018-0191-730622287
   PubMed Web of Science ®Google Scholar
• Fukuda H, Kato I, Furuya M, et al. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion. Virchows Arch. 2019;474(3):389–393. doi:10.1007/s00428-018-2509-830552521
   PubMed Web of Science ®Google Scholar
• Gandhi J, Malik F, Amin M, Argani P, Bahrami A. MiT family translocation renal cell carcinomas: a 15th anniversary update. Histol Histopathol. 2020;35(2):125–136. doi:10.14670/HH-18-15931489603
   PubMed Web of Science ®Google Scholar
• Rao Q, Williamson SR, Zhang S, Eble JN, Grignon DJ. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation–associated renal cell carcinoma compared with TFE3 or Cathepsin K immunohistochemical staining alone. Am J Surg Pathol. 2013;37(6):6. doi:10.1097/PAS.0b013e31827e17cb
   Web of Science ®Google Scholar
• Green W, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013;37(8):1150–1163. doi:10.1097/PAS.0b013e31828a69ae23715164
   PubMed Web of Science ®Google Scholar
• Kato I, Furuya M, Baba M, et al. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review. Histopathology. 2019;75(2):254–265. doi:10.1111/his.1386630908700
   PubMed Web of Science ®Google Scholar
• Pradhan D, Roy S, Quiroga-Garza G, et al. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma. Diagn Pathol. 2015;10(1):179. doi:10.1186/s13000-015-0412-z26415891
   PubMed Web of Science ®Google Scholar
• Hodge JC, Pearce KE, Wang X, Wiktor AE, Oliveira AM, Greipp PT. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. Mod Pathol. 2014;27(1):113–127. doi:10.1038/modpathol.2013.8323828314
   PubMed Web of Science ®Google Scholar
• Zhong M, De Angelo P, Osborne L, et al. Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol. 2010;34(6):757. doi:10.1097/PAS.0b013e3181dd577e20421778
   PubMed Web of Science ®Google Scholar
• Kim SH, Choi Y, Jeong HY, Lee K, Chae JY, Moon KC. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma. Virchows Arch. 2011;459(3):299–306. doi:10.1007/s00428-011-1127-521773754
   PubMed Web of Science ®Google Scholar
• Chen X, Yang Y, Gan W, Xu L, Ye Q, Guo H. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article. Medicine (Baltimore). 2015;94(19):e873. doi:10.1097/MD.000000000000087325984679
   PubMed Web of Science ®Google Scholar
• Yang B, Duan H, Cao W, et al. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis. Mod Pathol. 2019;32(10):1521–1535. doi:10.1038/s41379-019-0283-z31175325
   PubMed Web of Science ®Google Scholar
• Calio A, Grignon DJ, Stohr BA, Williamson SR, Eble JN, Cheng L. Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase B mutation. Mod Pathol. 2017;30(3):407–415. doi:10.1038/modpathol.2016.20027910947
   PubMed Web of Science ®Google Scholar
• Chou A, Hes O, Turchini J, Trpkov K, Gill AJ. Do significant TFE3 gene rearrangements occur in succinate dehydrogenase-deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution. Mod Pathol. 2017;30(10):1507–1508. doi:10.1038/modpathol.2017.7728972582
   PubMed Web of Science ®Google Scholar
• Williamson SR, Grignon DJ, Calio A, Stohr BA, Eble JN, Cheng L. Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution. Mod Pathol. 2017;30(10):1509–1511. doi:10.1038/modpathol.2017.8428972584
   PubMed Web of Science ®Google Scholar
• Xiong L, Chen X, Liu N, et al. PRCC-TFE3 dual-fusion FISH assay: a new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue. PLoS One. 2017;12(9):e0185337. doi:10.1371/journal.pone.018533728949976
   PubMed Web of Science ®Google Scholar
• Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas with t(6;11)(p21;q12): a clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012;36(9):1327–1338. doi:10.1097/PAS.0b013e31825aafb522895266
   PubMed Web of Science ®Google Scholar
• Mosquera JM, Cin PD, Mertz KD, et al. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol. 2011;20(3):129–137. doi:10.1097/PDM.0b013e31820e9c6721817901
   PubMedGoogle Scholar
• Camp R, Dolled-Filhart M, Rimm D. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-071315534099
   PubMed Web of Science ®Google Scholar
• Liu N, Gan W, Qu F, et al. Does the Fuhrman or World Health Organization/International Society of Urological Pathology Grading System apply to the Xp11.2 translocation renal cell carcinoma?: a 10-year single-center study. Am J Pathol. 2018;188(4):929–936. doi:10.1016/j.ajpath.2017.12.01829571325
   PubMed Web of Science ®Google Scholar
• Calio A, Segala D, Munari E, Brunelli M, Martignoni G. MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge. Cancers (Basel). 2019;11(8):1110. doi:10.3390/cancers11081110
   PubMed Web of Science ®Google Scholar
• Macher-Goeppinger S, Roth W, Wagener N, et al. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol. 2012;25(2):308–315. doi:10.1038/modpathol.2011.16922037260
   PubMed Web of Science ®Google Scholar
• Ma W, Liu N, Zhuang W, et al. Comparative clinicopathologic characteristics and outcomes of paediatric and adult Xp11 translocation renal cell carcinomas: a retrospective multicentre study in China. Sci Rep. 2020;10(1):2249. doi:10.1038/s41598-020-59162-532042048
   PubMed Web of Science ®Google Scholar
• Pan C, Sung M, Huang H, Yeh K. High chromosomal copy number alterations in Xp11 translocation renal cell carcinomas detected by array comparative genomic hybridization are associated with aggressive behavior. Am J Surg Pathol. 2013;37(7):1116–1119. doi:10.1097/PAS.0b013e318293d87223759936
   PubMed Web of Science ®Google Scholar
• Ellis CL, Eble JN, Subhawong AP, et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Mod Pathol. 2014;27(6):875–886. doi:10.1038/modpathol.2013.20824309327
   PubMed Web of Science ®Google Scholar
• Argani P, Olgac S, Tickoo S, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31(8):1149–1160. doi:10.1097/PAS.0b013e318031ffff17667536
   PubMed Web of Science ®Google Scholar
• Kurahashi R, Kadomatsu T, Baba M, et al. MicroRNA-204-5p: a novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. Cancer Sci. 2019;110(6):1897–1908. doi:10.1111/cas.1402631006167
   PubMed Web of Science ®Google Scholar